Brokerages Set Senti Biosciences, Inc. (NASDAQ:SNTI) Target Price at $8.50

Senti Biosciences, Inc. (NASDAQ:SNTI) has been assigned a consensus recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $8.50.

Several equities analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. Chardan Capital lowered their price objective on shares of Senti Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd.

Hedge Funds Weigh In On Senti Biosciences

Several institutional investors have recently made changes to their positions in SNTI. Armistice Capital LLC bought a new position in shares of Senti Biosciences in the 2nd quarter worth approximately $1,883,000. Geode Capital Management LLC lifted its stake in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the period. Citadel Advisors LLC bought a new position in shares of Senti Biosciences in the 3rd quarter worth approximately $117,000. Virtu Financial LLC bought a new position in shares of Senti Biosciences in the 4th quarter worth approximately $46,000. Finally, Jane Street Group LLC bought a new stake in Senti Biosciences during the 4th quarter worth approximately $40,000. Institutional investors own 25.70% of the company’s stock.

Senti Biosciences Stock Up 3.6%

Shares of NASDAQ SNTI opened at $1.14 on Monday. The firm’s 50-day moving average price is $0.92 and its 200-day moving average price is $1.32. Senti Biosciences has a 52-week low of $0.77 and a 52-week high of $5.10. The company has a market cap of $35.50 million, a PE ratio of -0.36 and a beta of 2.11.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $1.00 million. As a group, equities research analysts anticipate that Senti Biosciences will post -1.03 EPS for the current fiscal year.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.